Chargement en cours...
Pulmonary pharmacodynamics of an anti-GM-CSFRα antibody enables therapeutic dosing that limits exposure in the lung
Pulmonary alveolar proteinosis is associated with impaired alveolar macrophage differentiation due to genetic defects in the granulocyte macrophage colony-stimulating factor (GM-CSF) axis or autoantibody blockade of GM-CSF. The anti-GM-CSFRα antibody mavrilimumab has shown clinical benefit in patien...
Enregistré dans:
| Publié dans: | MAbs |
|---|---|
| Auteurs principaux: | , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Taylor & Francis
2016
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5058617/ https://ncbi.nlm.nih.gov/pubmed/27560702 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/19420862.2016.1215790 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|